Efficacy and Safety of Oral Semaglutide Versus Liraglutide and Versus Placebo in Subjects With Type 2 Diabetes Mellitus

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 711 participants.

Also called NCT02863419

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 711 participants (enrolled count) (from the registry)
Sponsor
  • Novo Nordisk Registry lists this organization as the lead sponsor
Registry
  • NCT NCT02863419
  • EudraCT 2015-005210-30
Main results
  • Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial Lancet (London, England), 2019-07-06 DOI, PubMed 31186120 PubMed links an erratum for this paper. Erratum: PMID 31282364
Other papers using this trial's data
  • Efficacy and safety of oral semaglutide in Japanese patients with type 2 diabetes: A post hoc subgroup analysis of the PIONEER 1, 3, 4 and 8 trials Diabetes, obesity & metabolism, 2021-12 DOI, PubMed 34472698, PMC9293331 In the PMC Open Access subset under CC BY-NC.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Croatia, Czechia, Germany, Hungary, Japan, Latvia, Poland, Puerto Rico, Slovakia, South Africa, Ukraine, United Arab Emirates (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02863419. Randomized; double masking; primary purpose treatment. Start 2016-08-10 (actual); primary completion 2017-08-19 (actual). Results posted on 2019-11-07.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of Oral Semaglutide Versus Liraglutide and Versus Placebo in Subjects With Type 2 Diabetes Mellitus
Acronym
PIONEER 4
Condition
Diabetes
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
semaglutide
Intervention (Drug)
liraglutide
Intervention (Drug)
placebo
Lead sponsor
Novo Nordisk A/S (class: industry)

Record details

Record id
cardio:ct-nct02863419
Content hash
733cbbbfdf1c7bb60f45c5c244ecffb785dc143b2afadec4b4a579d99e13e186